Establishment and Validation of Immune-Related Genes Diagnostic Model in Autoimmune Thyroiditis Based on RNA-seq

Our study used a cross-sectional survey as its foundation. Peripheral blood samples were taken from target subjects, which chosen by sampling. Ten cases were chosen as Training-set samples and eighty cases as Validation-set samples from all the samples. Following RNA sequencing (RNA-seq) of the Training-set samples, the result obtained was used as the Training-set to construct the diagnostic model. The Validation-set was made up of the model genes' expression in the Validation-set sample, which was detected by quantitative reverse transcription PCR (RT-qPCR). Utilizing bioinformatics technology, downloaded AIT sequencing datasets from the GEO database, combined and analyzed them to create the Test-set. Based on the Training-set, Validation-set, and Test-set, the diagnostic model's performance was thoroughly reviewed and assessed from a variety of angles. In addition to offering guidance for the diagnosis and prevention of AIT, which also effectively lowers the financial burden on patients and conserves scarce medical resources, this study may show the potential value of IRGs in the diagnosis of AIT to provide new insights for exploring the mechanism of AIT pathogenesis. It was anticipated that the diagnostic model will give researchers new tools for early prevention and diagnosis of AIT, help them identify populations with high risk efficiently, and support them in the hierarchical control of disease risk. Overall design: The diagnostic model was constructed and internally verified using the sequencing results that served as the Training-set. Five healthy individuals were matched as the Control group based on age, gender, BMI and home place after selecting five representative AIT patients as the AIT group. Trizol extracted total RNA from peripheral blood of total ten samples. The RNA concentration was measured on NanoDrop 2000/2000C (Thermo Fisher Scientific, Waltham, MA, USA). These RNA samples were subsequently subjected to RNA-seq on the DNBSEQ platform following standard procedures (Bgi Genomics Co., Ltd, Shenzhen, China).